Tempus AI, Inc. (NASDAQ:TEM – Get Free Report) CEO Ryan Fukushima sold 10,000 shares of Tempus AI stock in a transaction on Monday, July 6th. The stock was sold at an average price of $60.00, for a total transaction of $600,000.00. Following the sale, the chief executive officer directly owned 201,047 shares of the company’s stock, valued at approximately $12,062,820. This trade represents a 4.74% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.
Ryan Fukushima also recently made the following trade(s):
- On Tuesday, May 19th, Ryan Fukushima sold 13,550 shares of Tempus AI stock. The shares were sold at an average price of $44.07, for a total value of $597,148.50.
Tempus AI Trading Down 4.7%
Shares of Tempus AI stock opened at $57.27 on Thursday. The company’s fifty day moving average is $50.92 and its two-hundred day moving average is $54.35. Tempus AI, Inc. has a 1 year low of $41.73 and a 1 year high of $104.32. The company has a debt-to-equity ratio of 2.96, a quick ratio of 3.15 and a current ratio of 3.31. The company has a market capitalization of $10.28 billion, a P/E ratio of -33.30 and a beta of 3.46.
Analysts Set New Price Targets
A number of analysts have commented on TEM shares. Jefferies Financial Group began coverage on Tempus AI in a research report on Monday, April 13th. They set an “underperform” rating and a $35.00 target price on the stock. Needham & Company LLC reiterated a “buy” rating and set a $75.00 price objective on shares of Tempus AI in a research report on Monday, June 1st. Wall Street Zen downgraded Tempus AI from a “hold” rating to a “sell” rating in a research report on Saturday, July 4th. Freedom Capital raised shares of Tempus AI to a “hold” rating in a research report on Tuesday, June 30th. Finally, BTIG Research reaffirmed a “buy” rating and issued a $80.00 price objective on shares of Tempus AI in a research note on Monday, June 1st. Nine investment analysts have rated the stock with a Buy rating, four have given a Hold rating and two have given a Sell rating to the company. According to data from MarketBeat, Tempus AI currently has an average rating of “Hold” and an average target price of $68.54.
Read Our Latest Stock Analysis on TEM
Institutional Trading of Tempus AI
Several institutional investors have recently added to or reduced their stakes in TEM. Victory Capital Management Inc. raised its stake in Tempus AI by 1.5% during the third quarter. Victory Capital Management Inc. now owns 11,078 shares of the company’s stock valued at $894,000 after buying an additional 162 shares in the last quarter. US Bancorp DE boosted its stake in Tempus AI by 6.6% in the third quarter. US Bancorp DE now owns 2,848 shares of the company’s stock valued at $230,000 after acquiring an additional 176 shares during the period. Legacy Bridge LLC increased its position in Tempus AI by 1.6% in the fourth quarter. Legacy Bridge LLC now owns 12,418 shares of the company’s stock worth $733,000 after buying an additional 193 shares during the period. Truist Financial Corp lifted its stake in Tempus AI by 5.8% in the fourth quarter. Truist Financial Corp now owns 3,532 shares of the company’s stock valued at $209,000 after buying an additional 194 shares during the last quarter. Finally, Farther Finance Advisors LLC grew its position in shares of Tempus AI by 3.5% during the fourth quarter. Farther Finance Advisors LLC now owns 6,390 shares of the company’s stock worth $377,000 after acquiring an additional 219 shares during the last quarter. 24.22% of the stock is owned by institutional investors and hedge funds.
About Tempus AI
Tempus is a technology-driven healthcare company that applies artificial intelligence and machine learning to clinical and molecular data in order to advance precision medicine. Its primary focus lies in oncology, where the company offers comprehensive genomic profiling, digital pathology services and data-driven insights to inform personalized cancer care. By integrating DNA and RNA sequencing with structured clinical information, Tempus enables clinicians and researchers to identify targeted treatment options for patients based on the genetic characteristics of their tumors.
The company’s core offering centers on a scalable, cloud-based analytics platform that aggregates vast amounts of molecular and clinical data.
See Also
- Five stocks we like better than Tempus AI
- A Market Panic Just Discounted the AI Highway’s Tollbooth
- Why Exxon Could Be the Market’s Next Big Comeback Stock
- The Market Just Got Shaken—These 3 ETFs May Come Out Stronger
- Meta Platforms’ Cloud Push: Growth Opportunity Versus AI Concerns
Receive News & Ratings for Tempus AI Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Tempus AI and related companies with MarketBeat.com's FREE daily email newsletter.
